Search Result

Results for "

Bombesin Receptor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Bombesin Receptor (30) Akt (2) Apoptosis (2) Bacterial (2) Cholecystokinin Receptor (1) Drug Derivative (1) GSK-3 (2) Interleukin Related (1) JNK (1) LXR (2) MMP (2) mTOR (2) NF-κB (2) PI3K (2) Reactive Oxygen Species (ROS) (2) Reference Standards (2)
By Research Areas:	Cancer (17) Cardiovascular Disease (3) Endocrinology (1) Infection (2) Inflammation/Immunology (5) Metabolic Disease (10) Neurological Disease (9)

Inhibitors & Agonists

Peptides

Natural
Products

Targets Recommended: Bombesin Receptor

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P0195

Bombesin 1 Publications Verification	Bombesin Receptor	Neurological Disease Metabolic Disease
Bombesin, a tetradecapeptide, plays an important role in the release of gastrin and the activation of G-protein receptors .

HY-101844

ML-18	Bombesin Receptor	Cancer
ML-18 is a non-peptide bombesin receptor subtype-3 (BRS-3) antagonist with an IC₅₀ of 4.8 μM.

HY-14342

MK-5046 2 Publications Verification	Bombesin Receptor	Metabolic Disease
MK-5046 is a potent, selective and orally active Bombesin receptor subtype-3 (BRS-3) allosteric agonist with an IC₅₀ and an EC₅₀ value of 27 and 25 nM for hBRS-3, respectively. MK-5046 inhibits food intake and reduces body weight of diet-induced obese (DIO) mouse models. MK-5046 can be used for the research of obesity .

HY-N4247

Kuwanon G	Bombesin Receptor Bacterial Apoptosis Reactive Oxygen Species (ROS) PI3K Akt GSK-3 MMP mTOR NF-κB LXR	Infection Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
Kuwanon G is a flavonoid compound and an antagonist of the bombesin receptor. Kuwanon G has multiple activities such as bactericidal, anti-tumor, anti-inflammatory, antioxidant, anti-atherosclerotic, and neuroprotective effects. Kuwanon G exhibits strong antibacterial activity against oral pathogens, especially cariogenic bacteria and periodontal pathogens. Kuwanon G can induce apoptosis and inhibit proliferation, migration, and invasion of tumor cells. Kuwanon G can be used in the research of diseases such as gastric cancer and atherosclerosis .

HY-P0107A

RC-3095 TFA 1 Publications Verification	Bombesin Receptor	Inflammation/Immunology
RC-3095 TFA is a selective *bombesin/gastrin* releasing peptide receptor (GRPR) antagonist . RC-3095 TFA exerts protective effects by reducing gastric oxidative injury in the arthritic mice .

HY-N2600

Kuwanon H	Bombesin Receptor	Cancer
Kuwanon H is a flavonoid isolated from Morus alba, which acts as a potent non-peptide **bombesin receptor antagonist. Kuwanon H selectively inhibits binding of gastrin releasing peptide CRP to GRP-preferring recepotr, with a K_i** value of 290 nM in cells .

HY-P1423A

BA 1 TFA	Bombesin Receptor	Metabolic Disease Cancer
BA 1 TFA is a potent agonist for the *bombesin* (BB) family of receptors. BA1 binds with high affinity to Bombesin receptor subtype-3 (BRS3), gastrin releasing peptide receptor (GRPR), neuromedin B receptor (NMBR) with IC₅₀s of 6, 0.4, 2.5 nM .

HY-103281

Litorin	Bombesin Receptor	Metabolic Disease
Litorin, an amphibian bombesin peptide derivative, is an **bombesin receptor** agonist. Litorin stimulates the contraction of smooth muscle, stimulates gastrin, gastric acid, and pancreatic secretion, and suppresses the nutriment in vivo .

HY-P0107

RC-3095 1 Publications Verification	Bombesin Receptor	Inflammation/Immunology
RC-3095 is a *bombesin/gastrin* releasing peptide receptor (GRPR) antagonist . RC-3095 exerts protective effects by reducing gastric oxidative injury in the arthritic mice .

HY-P0039

BIM-26226	Bombesin Receptor	Cancer
BIM-26226 is a selective gastrin-releasing peptide receptor (GRPR) (IC₅₀ = 6 nM) and bombesin receptor (BN receptor) antagonist. BIM-26226 antagonizes BN- or GRP-stimulated amylase release with IC₅₀ values of 0.3 nM and 0.2 nM, respectively. BIM-26226 is specific for the GRP-preferring BN receptor subtype with no interference with GRP receptor system. BIM-26226 can induce the synthesis of somatostatin receptor but has no significant effect on tumor growth .

HY-P10896

NOTA-P2-RM26	Bombesin Receptor	Cancer
NOTA-P2-RM26 is an antagonist of Bombesin (HY-P0195) analogs, and the gastrin-releasing peptide receptor (GRPR/BB2) is a molecular target for prostate cancer visualization. NOTA-P2-RM26 is labeled with ¹¹¹In and ⁶⁸Ga for prostate cancer imaging studies using PET and SPECT/CT .

HY-103544

[D-Arg1,D-Phe5,D-Trp7,9,Leu11]-Substance P	JNK Interleukin Related Bombesin Receptor	Inflammation/Immunology Cancer
[D-Arg1,D-Phe5,D-Trp7,9,Leu11]-Substance P, a Substance P derivative, is a biased agonist toward neuropeptide and chemokine receptors. [D-Arg1,D-Phe5,D-Trp7,9,Leu11]-Substance P activates G12. [D-Arg1,D-Phe5,D-Trp7,9,Leu11]-Substance P binds to IL-8 and GRP receptors. [D-Arg1,D-Phe5,D-Trp7,9,Leu11]-Substance P inhibits ERK-2 activation, activates JNK activity. [D-Arg1,D-Phe5,D-Trp7,9,Leu11]-Substance P stimulates an increase in neutrophil migration and Ca ²⁺ mobilization. [D-Arg1,D-Phe5,D-Trp7,9,Leu11]-Substance P is also a *bombesin* antagonist, and inhibits the growth of small cell lung cancer

HY-W343750

[Tyr4]-Bombesin	Bombesin Receptor	Metabolic Disease
[Tyr4]-Bombesin is a Bombesin analogue, is a ligand of gastrin-releasing peptide receptor (GRPR) .

HY-P5413

[Lys3]-Bombesin	Cholecystokinin Receptor	Others
[Lys3]-Bombesin is a biological active peptide. (PET (Positron Emission Tomography) imaging of [Lys3]-bombesin is able to detect gastrin-releasing peptide receptor (GRPR) positive prostate cancer. An immunoconjugate of [Lys3]-bombesin and corresponding monoclonal antibody can specifically induce (CD64)-dependent monocyte and neutrophil-mediated lysis of small cell carcinoma.)

HY-P3112

ICI 216140	Bombesin Receptor	Neurological Disease
ICI 216140 is a *GRP/bombesin* receptor 2 antagonist with the IC₅₀** of 2 nM. ICI 216140 can reduce Bombesin (HY-P0195)-stimulated pancreatic amylase secretion and attenuates Bombesin (HY-P0195)-stimulated increases in blood pressure .

HY-103277A

BIM 23042 TFA 1 Publications Verification	Bombesin Receptor	Neurological Disease Metabolic Disease
BIM 23042 TFA, a certain somatostatin (SS) octapeptide analogue, is a selective neuropeptide neuromedin B receptor (NMB-R, BB1) antagonist. BIM 23042 has 100-fold lower affinity for gastrin-releasing peptide (GRP) receptor (BB2). BIM 23042 inhibits Neuromedin?B?(HY-P0241), ICI 216140 and DPDM-bombesin ethylamide-induced Ca ²⁺ release .

HY-103277

BIM 23042	Bombesin Receptor	Neurological Disease Metabolic Disease
BIM 23042, a certain somatostatin (SS) octapeptide analogue, is a selective neuropeptide neuromedin B receptor (NMB-R, BB1) antagonist. BIM 23042 has 100-fold lower affinity for gastrin-releasing peptide (GRP) receptor (BB2). BIM 23042 inhibits Neuromedin?B?(HY-P0241), ICI 216140 and DPDM-bombesin ethylamide-induced Ca ²⁺ release .

HY-P11352

JMV594 RM26	Bombesin Receptor	Cancer
JMV594 (Compound RM 26) is a bombesin analogue with high affinity and antagonistic effect for gastrin releasing peptide receptor (GRPR).JMV594 can be used for the research of cancer, such as Prostate cancer .

HY-14342A

(R)-MK-5046	Bombesin Receptor	Metabolic Disease
(R)-MK-5046 is the isomer of MK-5046 (HY-14342), and can be used as an experimental control. MK-5046 is a potent, selective and orally active Bombesin receptor subtype-3 (BRS-3) allosteric agonist with an IC₅₀ and an EC₅₀ value of 27 and 25 nM for hBRS-3, respectively. MK-5046 inhibits food intake and reduces body weight of diet-induced obese (DIO) mouse models. MK-5046 can be used for the research of obesity .

HY-P5072

GRP (14-27) (human, porcine, canine)	Bombesin Receptor	Metabolic Disease
GRP (14-27) (human, porcine, canine) is a bombesin receptor ligand. The specific binding of GRP (14-27) is inhibited by GTP and GDP, whereas GMP was without effect .

HY-P1423

BA 1	Bombesin Receptor	Metabolic Disease Cancer
BA 1 is a potent agonist for the *bombesin* (BB) family of receptors. BA 1 binds with high affinity to Bombesin receptor subtype-3 (BRS3), gastrin releasing peptide receptor (GRPR), neuromedin B receptor (NMBR) with IC₅₀s of 6, 0.4, 2.5 nM .

HY-176150

AMTG-DA1	Bombesin Receptor	Cancer
AMTG-DA1 is a Gastrin-releasing peptide receptor (GRPR) ligand. AMTG-DA1 can be used in the study of cancer .

HY-P1685

Ranatensin	Bombesin Receptor	Cardiovascular Disease Endocrinology
Ranatensin is a undecapeptide and a **Bombesin Receptor** angonist, can be isolated from amphibian skin, such as the frog, Rana pipiens. Ranatensin could maintain the dynamic balance of animal blood pressure, without cross-tachyphylaxis with Angiotensin amide (HY-P2212),Bradykinin (HY-P0206), or Norepinephrine (HY-13715) .

HY-N4247R

Kuwanon G (Standard)	Reference Standards Bombesin Receptor Bacterial Apoptosis Reactive Oxygen Species (ROS) PI3K Akt GSK-3 MMP mTOR NF-κB LXR	Infection Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
Kuwanon G (Standard) is the analytical standard of Kuwanon G (HY-N4247). This product is intended for research and analytical applications. Kuwanon G is a flavonoid compound and an antagonist of the bombesin receptor. Kuwanon G has multiple activities such as bactericidal, anti-tumor, anti-inflammatory, antioxidant, anti-atherosclerotic, and neuroprotective effects. Kuwanon G exhibits strong antibacterial activity against oral pathogens, especially cariogenic bacteria and periodontal pathogens. Kuwanon G can induce apoptosis and inhibit proliferation, migration, and invasion of tumor cells. Kuwanon G can be used in the research of diseases such as gastric cancer and atherosclerosis .

HY-17674

Bombesin receptor antagonist-1	Bombesin Receptor	Neurological Disease Cancer
Bombesin receptor antagonist-1 (Example 32) is a **bombesin receptor antagonist with K_i** values for neurotide B (NMB receptor) and gastrin-releasing peptide receptor (GRP receptor) of 0.17 and 20 nM respectively. Bombesin receptor antagonist-1 can be used to study various diseases, such as cancer, depression, and eating disorders .

HY-103287

[D-Phe12,Leu14]-Bombesin	Bombesin Receptor	Cancer
[D-Phe12,Leu14]-Bombesin is an antagonist of **Bombesin Receptor*. [D-Phe12,Leu14]-Bombesin* can be used for the research of cancer .

HY-103282

[D-Phe12]-Bombesin	Bombesin Receptor	Others
[D-Phe12]-Bombesin is a derivative of Bombesin (HY-P0195) and an antagonist for bombesin receptor with K_i of 4.7 μM. [D-Phe12]-Bombesin inhibits the Bombesin (HY-P0195)-induced amylase release, with IC₅₀ of 4 μM .

HY-N2600R

Kuwanon H (Standard)	Reference Standards Bombesin Receptor	Cancer
Kuwanon H (Standard) is the analytical standard of Kuwanon H. This product is intended for research and analytical applications. Kuwanon H is a flavonoid isolated from Morus alba, which acts as a potent non-peptide bombesin receptor antagonist. Kuwanon H selectively inhibits binding of gastrin releasing peptide CRP to GRP-preferring recepotr, with a Ki value of 290 nM in cells .

HY-17673

PD 168368 derivative-1	Drug Derivative Bombesin Receptor	Neurological Disease Cancer
PD 168368 derivative-1 (Compound 16) is a derivative of PD 168368 (HY-116216), with K_i values of 0.46 and 3.7 nM for the subtypes of **bombesin receptor (BB₁ and BB₂**). PD 168368 derivative-1 can be used for the study of various diseases, such as cancer, depression, and eating disorders .

HY-P11408

[D-Cys6,Asn7,D-Ala11,Cys14]-Bombesin (6-14)	Bombesin Receptor	Neurological Disease Cancer
[D-Cys6,Asn7,D-Ala11,Cys14]-Bombesin (6-14), a synthetic peptide, is a non-selective **bombesin receptor** agonist. [D-Cys6,Asn7,D-Ala11,Cys14]-Bombesin (6-14) has preferred pEC₅₀ values of 8.06 for the neurotrophin B bombesin receptor (BB1), 8.69 for the gastrin-releasing peptide bombesin receptor (BB2), and 6.71 for the orphan receptor (BB3). [D-Cys6,Asn7,D-Ala11,Cys14]-Bombesin (6-14) can be used to study diseases related to bombesin receptors, such as cancer and neurological disorders .

HY-P11768

AMBA	Bombesin Receptor	Cancer
AMBA is a gastrin-releasing peptide receptor (GRPR, BB2, BRS-2) ligand with a human IC₅₀ of 0.82 nM and a human K_i of 0.65 nM. AMBA binds to GRPR with high specificity and high affinity, and undergoes receptor-mediated endocytosis, which retains the conjugated radiometal in target cells. AMBA is applicable for the research of prostate cancer .

Cat. No.	Product Name	Target	Research Area

HY-P0195

Bombesin 1 Publications Verification	Bombesin Receptor	Neurological Disease Metabolic Disease
Bombesin, a tetradecapeptide, plays an important role in the release of gastrin and the activation of G-protein receptors .

HY-P0107A

RC-3095 TFA 1 Publications Verification	Bombesin Receptor	Inflammation/Immunology
RC-3095 TFA is a selective *bombesin/gastrin* releasing peptide receptor (GRPR) antagonist . RC-3095 TFA exerts protective effects by reducing gastric oxidative injury in the arthritic mice .

HY-P1423A

BA 1 TFA	Bombesin Receptor	Metabolic Disease Cancer
BA 1 TFA is a potent agonist for the *bombesin* (BB) family of receptors. BA1 binds with high affinity to Bombesin receptor subtype-3 (BRS3), gastrin releasing peptide receptor (GRPR), neuromedin B receptor (NMBR) with IC₅₀s of 6, 0.4, 2.5 nM .

HY-103281

Litorin	Bombesin Receptor	Metabolic Disease
Litorin, an amphibian bombesin peptide derivative, is an **bombesin receptor** agonist. Litorin stimulates the contraction of smooth muscle, stimulates gastrin, gastric acid, and pancreatic secretion, and suppresses the nutriment in vivo .

HY-P0107

RC-3095 1 Publications Verification	Bombesin Receptor	Inflammation/Immunology
RC-3095 is a *bombesin/gastrin* releasing peptide receptor (GRPR) antagonist . RC-3095 exerts protective effects by reducing gastric oxidative injury in the arthritic mice .

HY-P0039

BIM-26226	Bombesin Receptor	Cancer
BIM-26226 is a selective gastrin-releasing peptide receptor (GRPR) (IC₅₀ = 6 nM) and bombesin receptor (BN receptor) antagonist. BIM-26226 antagonizes BN- or GRP-stimulated amylase release with IC₅₀ values of 0.3 nM and 0.2 nM, respectively. BIM-26226 is specific for the GRP-preferring BN receptor subtype with no interference with GRP receptor system. BIM-26226 can induce the synthesis of somatostatin receptor but has no significant effect on tumor growth .

HY-P10896

NOTA-P2-RM26	Bombesin Receptor	Cancer
NOTA-P2-RM26 is an antagonist of Bombesin (HY-P0195) analogs, and the gastrin-releasing peptide receptor (GRPR/BB2) is a molecular target for prostate cancer visualization. NOTA-P2-RM26 is labeled with ¹¹¹In and ⁶⁸Ga for prostate cancer imaging studies using PET and SPECT/CT .

HY-103544

[D-Arg1,D-Phe5,D-Trp7,9,Leu11]-Substance P	JNK Interleukin Related Bombesin Receptor	Inflammation/Immunology Cancer
[D-Arg1,D-Phe5,D-Trp7,9,Leu11]-Substance P, a Substance P derivative, is a biased agonist toward neuropeptide and chemokine receptors. [D-Arg1,D-Phe5,D-Trp7,9,Leu11]-Substance P activates G12. [D-Arg1,D-Phe5,D-Trp7,9,Leu11]-Substance P binds to IL-8 and GRP receptors. [D-Arg1,D-Phe5,D-Trp7,9,Leu11]-Substance P inhibits ERK-2 activation, activates JNK activity. [D-Arg1,D-Phe5,D-Trp7,9,Leu11]-Substance P stimulates an increase in neutrophil migration and Ca ²⁺ mobilization. [D-Arg1,D-Phe5,D-Trp7,9,Leu11]-Substance P is also a *bombesin* antagonist, and inhibits the growth of small cell lung cancer

HY-W343750

[Tyr4]-Bombesin	Bombesin Receptor	Metabolic Disease
[Tyr4]-Bombesin is a Bombesin analogue, is a ligand of gastrin-releasing peptide receptor (GRPR) .

HY-P5413

[Lys3]-Bombesin	Cholecystokinin Receptor	Others
[Lys3]-Bombesin is a biological active peptide. (PET (Positron Emission Tomography) imaging of [Lys3]-bombesin is able to detect gastrin-releasing peptide receptor (GRPR) positive prostate cancer. An immunoconjugate of [Lys3]-bombesin and corresponding monoclonal antibody can specifically induce (CD64)-dependent monocyte and neutrophil-mediated lysis of small cell carcinoma.)

HY-P3112

ICI 216140	Bombesin Receptor	Neurological Disease
ICI 216140 is a *GRP/bombesin* receptor 2 antagonist with the IC₅₀** of 2 nM. ICI 216140 can reduce Bombesin (HY-P0195)-stimulated pancreatic amylase secretion and attenuates Bombesin (HY-P0195)-stimulated increases in blood pressure .

HY-103277A

BIM 23042 TFA 1 Publications Verification	Bombesin Receptor	Neurological Disease Metabolic Disease
BIM 23042 TFA, a certain somatostatin (SS) octapeptide analogue, is a selective neuropeptide neuromedin B receptor (NMB-R, BB1) antagonist. BIM 23042 has 100-fold lower affinity for gastrin-releasing peptide (GRP) receptor (BB2). BIM 23042 inhibits Neuromedin?B?(HY-P0241), ICI 216140 and DPDM-bombesin ethylamide-induced Ca ²⁺ release .

HY-103277

BIM 23042	Bombesin Receptor	Neurological Disease Metabolic Disease
BIM 23042, a certain somatostatin (SS) octapeptide analogue, is a selective neuropeptide neuromedin B receptor (NMB-R, BB1) antagonist. BIM 23042 has 100-fold lower affinity for gastrin-releasing peptide (GRP) receptor (BB2). BIM 23042 inhibits Neuromedin?B?(HY-P0241), ICI 216140 and DPDM-bombesin ethylamide-induced Ca ²⁺ release .

HY-P11352

JMV594 RM26	Bombesin Receptor	Cancer
JMV594 (Compound RM 26) is a bombesin analogue with high affinity and antagonistic effect for gastrin releasing peptide receptor (GRPR).JMV594 can be used for the research of cancer, such as Prostate cancer .

HY-P5072

GRP (14-27) (human, porcine, canine)	Bombesin Receptor	Metabolic Disease
GRP (14-27) (human, porcine, canine) is a bombesin receptor ligand. The specific binding of GRP (14-27) is inhibited by GTP and GDP, whereas GMP was without effect .

HY-P1423

BA 1	Bombesin Receptor	Metabolic Disease Cancer
BA 1 is a potent agonist for the *bombesin* (BB) family of receptors. BA 1 binds with high affinity to Bombesin receptor subtype-3 (BRS3), gastrin releasing peptide receptor (GRPR), neuromedin B receptor (NMBR) with IC₅₀s of 6, 0.4, 2.5 nM .

HY-P1685

Ranatensin	Bombesin Receptor	Cardiovascular Disease Endocrinology
Ranatensin is a undecapeptide and a **Bombesin Receptor** angonist, can be isolated from amphibian skin, such as the frog, Rana pipiens. Ranatensin could maintain the dynamic balance of animal blood pressure, without cross-tachyphylaxis with Angiotensin amide (HY-P2212),Bradykinin (HY-P0206), or Norepinephrine (HY-13715) .

HY-103287

[D-Phe12,Leu14]-Bombesin	Bombesin Receptor	Cancer
[D-Phe12,Leu14]-Bombesin is an antagonist of **Bombesin Receptor*. [D-Phe12,Leu14]-Bombesin* can be used for the research of cancer .

HY-103282

[D-Phe12]-Bombesin	Bombesin Receptor	Others
[D-Phe12]-Bombesin is a derivative of Bombesin (HY-P0195) and an antagonist for bombesin receptor with K_i of 4.7 μM. [D-Phe12]-Bombesin inhibits the Bombesin (HY-P0195)-induced amylase release, with IC₅₀ of 4 μM .

HY-P11408

[D-Cys6,Asn7,D-Ala11,Cys14]-Bombesin (6-14)	Bombesin Receptor	Neurological Disease Cancer
[D-Cys6,Asn7,D-Ala11,Cys14]-Bombesin (6-14), a synthetic peptide, is a non-selective **bombesin receptor** agonist. [D-Cys6,Asn7,D-Ala11,Cys14]-Bombesin (6-14) has preferred pEC₅₀ values of 8.06 for the neurotrophin B bombesin receptor (BB1), 8.69 for the gastrin-releasing peptide bombesin receptor (BB2), and 6.71 for the orphan receptor (BB3). [D-Cys6,Asn7,D-Ala11,Cys14]-Bombesin (6-14) can be used to study diseases related to bombesin receptors, such as cancer and neurological disorders .

HY-P11768

AMBA	Bombesin Receptor	Cancer
AMBA is a gastrin-releasing peptide receptor (GRPR, BB2, BRS-2) ligand with a human IC₅₀ of 0.82 nM and a human K_i of 0.65 nM. AMBA binds to GRPR with high specificity and high affinity, and undergoes receptor-mediated endocytosis, which retains the conjugated radiometal in target cells. AMBA is applicable for the research of prostate cancer .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Bombesin Receptor

Inhibitors & Agonists

Peptides

NaturalProducts

Natural
Products